Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Axia Dones Rodriguez

Critical Care Medicine Caguas, PR Medical Doctor

NPI 1457795072 CMS profile 945649

#100 Ave Luis Munoz Marin, Caguas, PR 00725

Open in the dashboard

General payments

$2,216

59 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Axia Dones Rodriguez of Caguas, PR is reported in the CMS Open Payments database as having received $2,216 across 59 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $72 1
2022 General $21 3
2021 General $50 1
2020 General $293 10
2019 General $1,779 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Axia Dones Rodriguez
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Axia Dones Rodriguez were reported at $0. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Axia Dones Rodriguez Critical Care Medicine median Middle half National median
2019 $1,779 $149 $51–$535 $163
2020 $293 $110 $30–$325 $114
2021 $50 $125 $34–$403 $132
2022 $21 $157 $49–$582 $149
2023 $0 $162 $56–$621 $160
2024 $72 $168 $53–$634 $164
2025 $0 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. GlaxoSmithKline, LLC. $579 11 payments
  2. Genentech USA, Inc. $393 8 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $306 12 payments
  4. AstraZeneca Pharmaceuticals LP $288 6 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $209 6 payments
  6. Shire North American Group Inc $98 1 payment
  7. Janssen Pharmaceuticals, Inc $73 3 payments
  8. Medtronic, Inc. $72 1 payment
  9. Chiesi USA, Inc. $50 1 payment
  10. Grifols USA, LLC $36 2 payments
  11. Other $111 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,166 58 payments
  2. Gift $50 1 payment
Products named General payments · program years 2019–2024
  1. Adempas $306 12 payments
  2. NUCALA $293 3 payments
  3. Esbriet $243 7 payments
  4. TRELEGY ELLIPTA $240 2 payments
  5. FASENRA $168 5 payments
  6. DALIRESP $120 1 payment
  7. Xolair $113 5 payments
  8. OFEV $106 5 payments
  9. GLASSIA $98 1 payment
  10. Micra $72 1 payment
  11. Other $341 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

123

Median for Critical Care (Intensivists): 406

Drug cost

$6,197

Median for Critical Care (Intensivists): $197,260

Branded share of claims

52%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Wixela Inhub Fluticasone Propion/Salmeterol Brand 24 $3,794
Albuterol Sulfate Hfa Albuterol Sulfate Brand 40 $1,677
Fluticasone Propionate Generic 27 $394
Montelukast Sodium Generic 32 $332

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Records

59 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record